Fiala

Peptide library › Growth hormone axis

Pegvisomant

Also known as Somavert

FDA-approved drugGrowth hormone axis

Blocks growth hormone's effects; used for acromegaly, a condition caused by too much growth hormone.

What people use it for

What Pegvisomant does in the body

A modified growth hormone that sticks to the growth hormone receptor without switching it on, so the body's own growth hormone can't act. This brings IGF-1 levels down.

Strength of evidence

Strong: normalises IGF-1 in most people with acromegaly in trials and long-term studies.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

FDA-approved in 2003. Prescription only.

How it's taken

Route: Injection under the skin, daily

How long it lasts (half-life): About 6 days

Latest research & news

Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.

Keep track of Pegvisomant privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Pegvisomant in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Growth hormone axis